Biotech · Public company · Newton, MA, US

Karyopharm Therapeutics Inc.

Ticker KPTI · SEC CIK 0001503802

Track this companyFree. Adds Karyopharm Therapeutics Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2520 recruiting or active

Pipeline programs17From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline17

Rituximab (combination therapy)Phase 3 · Relapsed/Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
RuxolitinibPhase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
SelinexorPhase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
SelinexorPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
Selinexor (combination therapy)Phase 3 · Relapsed/Refractory Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
BortezomibPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
DaratumumabPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
DexamethasonePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
LenalidomidePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
MomelotinibPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
PacritinibPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Physician's Choice TreatmentPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
PomalidomidePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
SelinexorPhase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
SelinexorPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Selinexor 40 mgPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Selinexor 60 mgPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasPHASE2 · RECRUITING · started Oct 23, 2026ClinicalTrials.gov NCT07447817 · fetched Nov 12, 2026
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaPHASE1_PHASE2 · RECRUITING · started May 21, 2026ClinicalTrials.gov NCT07479979 · fetched Nov 12, 2026
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaPHASE1 · RECRUITING · started Mar 17, 2026ClinicalTrials.gov NCT07200102 · fetched Nov 12, 2026
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)RECRUITING · started Sep 26, 2025ClinicalTrials.gov NCT07362225 · fetched Nov 12, 2026
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Aug 14, 2024ClinicalTrials.gov NCT06399640 · fetched Nov 12, 2026
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaPHASE2 · RECRUITING · started Apr 22, 2024ClinicalTrials.gov NCT05980806 · fetched Nov 12, 2026
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian CancerPHASE2 · RECRUITING · started Nov 16, 2023ClinicalTrials.gov NCT05983276 · fetched Nov 12, 2026
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaPHASE2 · RECRUITING · started Aug 21, 2023ClinicalTrials.gov NCT05597345 · fetched Nov 12, 2026
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 18, 2023ClinicalTrials.gov NCT05611931 · fetched Nov 12, 2026
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaPHASE2 · RECRUITING · started Mar 26, 2023ClinicalTrials.gov NCT05530421 · fetched Nov 12, 2026
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 18, 2021ClinicalTrials.gov NCT04925193 · fetched Nov 12, 2026
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 15, 2021ClinicalTrials.gov NCT04898894 · fetched Nov 12, 2026
Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 10, 2021ClinicalTrials.gov NCT04782687 · fetched Nov 12, 2026
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid LeukemiaPHASE1 · COMPLETED · started Aug 27, 2021ClinicalTrials.gov NCT04914845 · fetched Nov 12, 2026
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaPHASE1_PHASE2 · TERMINATED · started Apr 8, 2021ClinicalTrials.gov NCT04856189 · fetched Nov 12, 2026
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 17, 2021ClinicalTrials.gov NCT04562870 · fetched Nov 12, 2026
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaPHASE2 · RECRUITING · started Mar 16, 2021ClinicalTrials.gov NCT04661137 · fetched Nov 12, 2026
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 11, 2021ClinicalTrials.gov NCT04562389 · fetched Nov 12, 2026
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 3, 2020ClinicalTrials.gov NCT04442022 · fetched Nov 12, 2026
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic MalignanciesPHASE1 · COMPLETED · started Jun 21, 2019ClinicalTrials.gov NCT03955783 · fetched Nov 12, 2026
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsPHASE2 · TERMINATED · started May 10, 2019ClinicalTrials.gov NCT03627403 · fetched Nov 12, 2026
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]PHASE3 · COMPLETED · started Jan 5, 2018ClinicalTrials.gov NCT03555422 · fetched Nov 12, 2026
Selinexor and Backbone Treatments of Multiple Myeloma PatientsPHASE1_PHASE2 · RECRUITING · started Oct 1, 2015ClinicalTrials.gov NCT02343042 · fetched Nov 12, 2026
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 1, 2014ClinicalTrials.gov NCT02227251 · fetched Nov 12, 2026
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 1, 2014ClinicalTrials.gov NCT02091245 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 14, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 18, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 31, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026